In contrast to previous findings from glioblastoma mouse models, where TAMs survived CSF1R inhibition and were instead re-educated (169, 170), a recent work demonstrated that targeting TAMs with the CSF1R inhibitor BLZ945 delayed brain metastatic onset and led to an initial tumor response with transient stasis of established metastases (232).CSF1R inhibitors have also been evaluated in combination treatments in preclinical studies. Here, CSF1R is linked to glioblastoma.